Research programme: LRRK2 inhibitors - Halia Therapeutics
Latest Information Update: 28 Jul 2026
At a glance
- Originator Halia Therapeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Jul 2026 No recent reports of development identified for research development in Parkinson's-disease in USA
- 21 Jun 2022 Early research in Parkinson's disease in USA (unspecified route) before June 2022 (Halia Therapeutics pipeline, June 2022)